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Background.Anthroposophicmedicineisoneofthewidelyusedapproaches ofcomplementaryandalternativemedicine.However,
few prospective studies have generated safety data on its use. Objectives. We aimed to assess adverse drug reactions (ADRs) caused
by anthroposophical medicines (AMEDs) in the anthroposophical Community Hospital Havelhoehe, GERMANY. Study Design
and Methods. Between May and November 2007, patients of six medical wards were prospectively assessed for ADRs. Suspected
ADRs occurring during hospitalization were documented and classiﬁed in terms of organ manifestation (WHO SOC-code),
causality (according to the Uppsala Monitoring Centre WHO criteria), and severity. Only those ADRs with a severity of grade
2 and higher according to the CTCAE classiﬁcation system are described here. Results. Of the 3,813 patients hospitalized, 174
patients (4.6%) experienced 211 ADRs (CTCAE grade 2/3 n = 191, 90.5%, CTCAE grade 4/5 n = 20, 9.5%) of which 57 ADRs
(27.0%) were serious. The median age of patients with ADRs (62.1% females) was 72.0 (IQR: 61.0; 80.0). Six patients (0.2%)
experienced six ADRs (2.8% of ADRs) caused by eight suspected AMEDs, all of which were mild reactions (grade 2). Conclusion.
Our data show that ADRs caused by AMEDs occur rarely and are limited to mild symptoms.
1.Introduction
The term“complementaryand alternative medicine” (CAM)
describesa varietyofapproachestomedicaltheory andprac-
tice including homeopathy, herbal medicine, naturopathy,
anthroposophicmedicine,and traditionalChinesemedicine,
all of which are becoming increasingly accepted by practi-
tioners of conventional medicine [1, 2]. One of the main
reasons for such a high levelofinterest and demand forcom-
plementary medicine is the belief of patients and physicians
that “natural” products or services are safer than conven-
tional allopathic products [3]. Although there is substantial
evidence that herbal medicines can cause serious adverse
reactions [4], there is still a lack of knowledge on the occur-
rence of adverse reactions to CAM [5].
Anthroposophic medicine is one of the most frequent-
ly used traditional European approaches of CAM which
involvestheuseofavarietyoftherapies,includingart,music,
eurythmy (movement therapy), massage, and counselling as
well as anthroposophic medicines (AMEDs) [6, 7]. Anthro-
posophical pharmacotherapy uses substances from the min-
eral, plant, and animal kingdoms [8, 9]. Substances undergo
a variety of pharmaceutical processes and are applied in
many diﬀerent dilutions like in homeopathy, but also in dif-
ferent preparations and combinations. Apart from drug in-
take,AMEDsmay also beapplied as external treatments with
oils, ointments, and plant extracts.
Only few prospective studies have generated safety data
on AMEDs and most of them result from outpatient inves-
tigations. In a prospective cohort study in 662 patients using
AMED chronically only 20 patientsreported possible or pro-
bable ADRs associated with AMED, none of them was seri-
ous [10, 11]. In particular, no data have been reported so far
on AMED-associated ADRs occurring in hospitals.2 Evidence-Based Complementary and Alternative Medicine
In contrast, the nature and frequency of ADRs following
the use of conventional drugs in hospitalized patients have
been thoroughly studied in recent years [12–14]. Thus, com-
prehensiveADR surveillancein a hospitalsetting promises to
be an eﬃcient tool to detect all kind of ADRs and all grades
of severity.
The aim of this prospective pharmocoepidemiological
study was to estimate the incidence of adverse drug reactions
(ADRs) with a special focus on ADRs caused by CAM and,
in particular, AMEDs. We therefore conducted this study in
a community hospital, where AMEDs are frequently used
along with conventional drugs and therapies. In order to
provide for a valid basis of our detection method and to
prove comprehensiveness, ADRs associated with the use of
allopathic pharmaceuticals used were also collected and can
be compared with data published in the international litera-
ture [15–17].
2.MaterialandMethods
2.1. Patients. A prospective, comprehensive collection of
ADRs on six medical wards, including two gastroenterology
wards, two general internal medicine wards, one pneumol-
ogy ward, and one cardiology ward, was carried out at the
Community Hospital Havelh¨ ohe (GKH) in Berlin overa six-
month period between May 15 and November 15, 2007. The
GKH is a community hospital with a focus on anthropo-
sophic medicine where about 63% of inpatients on medical
wards receive one or more CAM drugs (median 3 (IQR: 1;
5)), of which 92% receive at least one AMED (median 3
(IQR:1;5);personal communication),thatis, approximately
58% of all patients admitted receive an AMED.
Almost half of patients (46%) in this study came from
the geographical catchment area, 32.9% of patients admitted
came from further regions within Berlin (approx. 30km),
and 21.1% were admitted from other regions in Germany or
from abroad. The latter came to the GKH with the intention
of receiving anthroposophic medicine.
2.2. Anthroposophic Medications (AMEDs) Used in Hospital.
For this study, we used data from the hospital pharmacy to
describe usage of the most frequently prescribed substances
during the study period on the wards under surveillance,
regardless of dilution, pharmaceutical processing, or com-
bination with other substances (Table 1). For example, the
frequently prescribed plant Arnica montana is included in 19
diﬀerent preparations of AMEDs (i.e., whole plant and root
preparations in 4 diﬀerent dilutions, preparations of Arnica
processed with four other plants, essence, gel, ointment, and
oil in combination with cuprum), which are administered
orally, subcutaneously, or externally.
2.3. Comprehensive ADR Surveillance and Data Collection.
Prior to investigation, the physicians and nurses of all par-
ticipating wards were trained in order to increase awareness
for ADRs according to a program developed for an edu-
cational intervention to improve primary care physicians
ADRreporting[18].BesidesprinciplesandtheoriesofADRs,
typical ADR trigger symptoms and case studies were dis-
cussed. Clinical staﬀ w a si n v i t e dt or e f e rd i r e c t l yo rb yp h o n e
to the investigator to report potential ADRs.
Aspeciallytrainedphysicianconductedtheinvestigation.
She visited the wards three times a week, questioned attend-
ing physicians and nurses, and examined the patients’ drug
charts and medical records for evidence of potential ADRs.
A set of trigger symptoms used by the German Network
of Pharmacovigilance Centers [19] was applied as were
changesin medicationand predeﬁnedlaboratory parameters
surpassing speciﬁed threshold values (according to CTCAE
criteria more than grade II) [20], for detection of ADRs.
Nurses’ notes were screened for subjective symptoms, such
as nausea, vomiting, or headache. Incase ofsuspected ADRs,
the investigator conferred with the attending physicians and
nurses.
Patient data collected included age, gender, weight,
height, date of admission and discharge, Kanofsky index (if
applicable), all diagnoses (ICD-10), and drugs (dose, route,
and duration of administration). ADR description included
start, duration and outcome, suspected drug(s), and man-
agement strategies (e.g., drug withdrawal, dose reduction,
and additional treatment).
Patients with ADRs obviously resulting in hospital ad-
mission and chemotherapy-induced ADRs (such as nausea,
vomiting, and leucopenia) were excluded in the study pro-
tocol. Recurrences of clostridium-associated diarrhea were
subsumed as one ADR.
2.4. Assessment and Classiﬁcation of ADRs. ADRs were clas-
siﬁed according to the deﬁnition of Edwards and Aronson
[21]. We restricted ADR classiﬁcation to type A, pharma-
cologic eﬀects which are dose dependent and predictable,
and type B, eﬀects which are dose independent and unpre-
dictable, which are the most frequent and accessible types
of ADRs recognized in the literature. CIOMS criteria were
applied for case deﬁnitions [22]. As sources of information
for the veriﬁcation of potential adverse eﬀects, the manufac-
turer’s summary of product characteristics [23], Lexi-Comp
Online [24], a Handbook of ADRs [25], and Medline search
were used.
Suspected ADRs were assessed and deﬁned according to
internationally accepted criteria [22] and classiﬁed in terms
oforganmanifestation (WHOSOC-code),causality[26,27],
and severity [20]. Causality was deﬁned and assessed accord-
ing to deﬁnitions of the Uppsala Monitoring Centre and
w a sc l a s s i ﬁ e da sc e r t a i n ,p r o b a b l e/likely, possible, unlikely,
conditional/unclassiﬁed,orunassessable/unclassiﬁable. Only
“possible,” “probable,” and “deﬁnite” ADRs were taken into
consideration; such were also classiﬁed in terms of causality
according to Naranjo et al. [26]. Furthermore, ADRs were
classiﬁed according to the International Conference on Har-
monization criteria as serious and nonserious, as well as in
terms of severity according to the Common Terminology
Criteria for Adverse Events (CTCAE) in grades 1 to 5 (mild-
letal) [20, 26, 28, 29].
Assessment for causality and severity was done indepen-
dently by at least two investigators. Internal quality assur-
ance proceedings were arranged in regular meetings withEvidence-Based Complementary and Alternative Medicine 3
Table 1: Most frequently prescribed anthroposophic medications (AMEDs) based on plant and metal preparationsa at the Community
Hospital Havelhoehe.
Plant/metala Main indication Ampoules
[mL]
Dilutions
[mL]
Triturations
[g]
Tablets
[n]
Ointments/oils
[g]
Kalanchoe daigremontiana/pinnata
(cathedral bells)
Psychic agitation, restlessness,
and anxiety 4512 200 745
Viscum album (mistletoe extract) Cancer 2251
Aconitum napellus (monkshood) (Neuropathic) Pain 1468 500 20000
Aurum (gold) Harmonisationof salutogenic
forces 1570 2700 50 3500
Argentum (silver) Activation of anabolic processes 1330 90
Arnica montana (arnica) Traumatic injury 638 4210 18820
Fragaria vesca/Vitis vinifera
(strawberry/vine leaves) Toxic hepatic damage 8200
aComprising plants and metals in diﬀerent concentrations, partly also in combination with other ingredients.
the clinical pharmacologist. In addition, if any discrepancies
in scoring were discussed between the investigators in con-
junction with the clinical pharmacologist, speciﬁc medical
questions were reconsidered with the respective medical
specialist. The consent attained this way was accepted as the
ﬁnal ADR classiﬁcation.
2.5. Mistletoe-Induced ADRs. Although mistletoe (Viscum
album) can be considered a herbal chemotherapeutic agent
due to its cytotoxic properties, we decided to include mis-
tletoe-associated ADRs although ADRs following allopathic
cytotoxic drugs had been excluded. Other characteristics,
such as modulation of the immune system, have been shown
for mistletoe [30–33]. As a consequence, mistletoe is pre-
scribed as a remedy for diverse diseases, for example, rheu-
matological diseases, hepatitis, and cancer and can be coded
using three diﬀerent ATC codes (L01CP01 plant cytostatics,
M09AP06 plant preparations for musculoskeletal disorders,
and C02KP02 plant antihypertensive).
Due to its immunomodulating properties mistletoe pro-
vokes local (reddening and swelling) and systemic (rise in
temperature/fever) reactions, which can be considered type
A reactions according to Rawlins [34].
Reactions exceeding the expected measure were classiﬁed
separately for intravenous or local application and docu-
mented in a special section in the database. The criteria are
listed below and follow CTCAE criteria: increase of body
temperature axillary >38.0◦C (CTCAE II◦, hypersensitivity
including drug reaction); reddening at the assured injection
site >50mm (CTCAE I); itching exceeding the injection
site (CTCAE II, pruritus/itching); local swelling >10mm
(CTCAE II◦II); swelling of the lymph node >10mm; unex-
pected, uncharacteristic reaction.
2.6. Collection and Documentation of Drug Prescriptions.
Data on medicines prescribed in the hospital were collected
and recorded manually. In order to achieve a high complete-
ness of data, the recording of all drugs, including causative
drugs, was performed only for patientswith an ADR and not
for patients without a suspected ADR.
ADR-associated drugs were classiﬁed by the anatomical
therapeutic chemical (ATC) code.
2.7. Data Analysis. Collected data were structured hierarchi-
cally, allowing for evaluation of a patient and the admission
and ADR level using the database QuaDosta, a PostgreSQL
database [35]. All statistical analyses were performed using
SPSS 16.0 for Windows. Descriptive analysis was used to
determine patients with ADRs and ADR frequencies accord-
i n gt oSOCc o d e ,A T Cc o d e ,a n ds ev e ri ty .M e d i a n sa n di n t e r -
quartile ranges (IQRs) were calculated for continuous, not
normally distributed data. The two-tailed chi-square test was
used to analyze diﬀerences in proportions and the median
test was usedtoanalyzeagediﬀerences.AP-valueoflessthan
0.05 was regarded as indicating a statistically signiﬁcant dif-
ference. Subgroup analyses were performed for drug groups
according to ATC code.
3.Results
3.1. Patient Characteristics. Over a six-month period, a total
of 3,813 patients (2,063 females; 54.1%) with a mean age
of 67 ± 10 years, median 55 years, were admitted, stayed at
least one night, and were assessed for ADRs (Table 2).
The leading admittance diagnoses were coronary heart
disease (5.9%), fatigue (3.5%), dyspnoea (2.7%), pain
(2.7%), pneumonia (2.2%), and lung cancer (2.2%).
12.9% of the patients had diﬀerent types of cancer, 3.5%
received chemotherapy, and 9.1% received mistletoe during
the hospital stay.
174 patients (4.6%) experienced at least one ADR during
their stay in hospital (ADR).The ADR-experiencing patients
were more likelyto be female (62.1%females, P<0.001)and
older when compared to patients without ADR (median age
72 years, IQR 61.0; 80.0, see Table 2, P<0.001).
3.2. ADRs. A total of 211 ADRs (including the 6 ADRs
caused by CAM) were detected and documentedon the basis
of WHO/UMC criteria. They were judged as probable in
123 cases (59%), 72 were judged as likely (34%), and 10 as4 Evidence-Based Complementary and Alternative Medicine
Table 2: Demographic data of admitted patients and of patients
suﬀering from ADRsa.
Patients with ADR Hospitalized patients
Number (%) 174 (4.6) 3813
Gender (n male/n
female, %) 43/131 (62.1)∗∗ 1750/2063 (54.1)
Age (median, IQR) 72, 61.0; 80.0 ∗∗ 67, 55.0; 77.0
aMultiple hospitalizations of the patients were counted as separate cases of
the same patient. ∗∗P<0.001 all hospitalized versus patients with ADR.
deﬁnite (5%). This assessment was in good accordance
with the Naranjo scoring, where 105 ADRs were considered
probable (49.8%), 99 possible (46.9%), and seven as highly
probable (3.3%).The greater number of ADRs with n = 184
(84.4%) were identiﬁed as type A reactions.
Distribution of severity and seriousness of ADR is shown
in Table 3. The majority of ADRs were of severity grades II
and III and 26.1% were deemed serious according to [36]
(see Table 3). Of these 55 serious ADRs, 33 led to a pro-
longation of the hospital stay and 20 were life threatening
or potentially life threatening. Eleven patients with serious
ADRsdidnotfully recover,two patientsdied:onefromacute
renal failure (vancomycin and gentamicin) and one from
Salmonella sepsis (prednisolone).
All 156 nonserious ADRs abated without sequelae and
the outcome of four patients was unknown.
The organ systems mainly aﬀectedwere thegastrointesti-
nal tract (n = 110, 52%; main symptoms: diarrhea n = 23,
constipation n = 22, nausea n = 18, GI-bleeding n = 8, and
gastric ulcern = 6), the CNS(n = 35, 17%; main symptoms:
vertigo n = 7, somnolence n = 5, and headache n = 3),
and psychiatric disorders (n = 24, 11.4%; main symptoms:
psychosisn = 3,disorientationn = 2,andaggressiveness n =
2). The most frequent adverse eﬀects overall were diarrhea,
constipation, nausea, and antibiotic-associated diarrhea.
3.3. Drugs Associated with ADRs. Altogether 389 (multiple
nominations possible) drugs were associated with 211ADRs.
All drugs causing the ADRs were initiated in the hospital.
The most common groups of ADR-related drugs were anti-
infectives (n = 124, 32%)followed by opiates(n = 45, 12%),
cardiovascular drugs (n = 59, 12.3%), steroids (n = 35, 9%),
and antithrombotics (n = 34, 8.7%) (see Table 4).
3.4. ADRs Associated with AMED Medication. Altogether
only six CAM-associated ADRs were detected. All associated
medicaments were AMEDs. According to the CTCAE scale,
all ADRs were grade II and none were serious. All patients
had recovered from these ADRs at the time of discharge.
Table 5 shows details of AMED-associated ADRs. Assuming
that approximately 58% of all patients admitted during the
surveillance period received AMED, only 0.27% (6 of 2212
AMED-exposed patients) suﬀered an AMED-associated
ADR.
All three mistletoe reactions (erythema and fever) oc-
curred between 18 and 24 hours after injection, as well as
Table 3: Characterization of adverse drug reactions (ADRs) of
hospital in-patients according to severity grade and seriousness.
ADR characteristics
Total number identiﬁed 211
Severity grade CTCAE (n,% )
II/III 191, 90.5%
IV/V 19, 9.5%
Serious (n, %) 55, 26.1%
the erythema after the injection of Equisetum, Formica,
Arnica, and Levisticum.
The maculopapular exanthema after hepatodoron (Fra-
garia vesca/Vitis vinifera)a ﬀecting both forearms appeared
two days after the ﬁrst oral application of the drug and was
considered a type IV reaction. The skin eruption appearing
on the chest of the patient about 5 hours after the ﬁrst oral
application of Gentiana, Bryophyllum, and metamizole was
judged to be a type II (cytotoxic) reaction.
4.Discussion
To our knowledge, this is the ﬁrst prospective study on the
burdenofadversedrugreactions(ADRs)ina hospital,where
patients are treated with standard drugs and complementary
and alternative medicine (CAM). In this speciﬁc case,
most patients were treated with anthroposophic medicine
(AMED). In order to demonstrate the comprehensiveness of
our detection method, ADRs caused by conventional drugs
were also captured. In comparison with the literature, the
estimation of 4.6% of all hospitalised patients with ADRs in
our study is comparable to the results of a systematic review
from 2002 by Wiﬀen and colleagues [37], who estimated an
ADR incidence of 3.7% worldwide from studies undertaken
after 1985. Our results also compare well with ﬁndings of
Moore et al. on internal medicine wards where 6.6% of all
patients suﬀered from ADRs [38]. However, Lazarou at al.
estimated an ADR incidence of 10.9% in their meta-analysis
of 39 prospective studies undertaken in American hospitals
between 1966 and 1996 [15]. We excluded ADRs associated
with chemotherapy, which are generally expected and also
not recorded in some of the studies [37, 39]. Fattinger et
al. report the ADR incidence of 11% in two Swiss hospitals,
which is reduced after the exclusion of chemotherapy-
induced ADRs to 8% [40].
When looking at drug classes responsible for ADRs, our
resultsalso correspond to datain the literature,where antibi-
otics,opioids,antithrombotics,andcardiovascularagentsare
themostfrequentlydocumenteddrugsassociatedwithADRs
in hospitalized patients [39].
Discrepancies in results of all ADR studies are well
known, mainly methodological diﬀerences have been found
responsible and were thoroughly investigated and described
[37, 39, 41]. Taken together, nature and frequency of the
ADRs in our study compare well with data published in
the literature for a comprehensive collection of ADRs in
hospitals and prove the reliability of our approach.Evidence-Based Complementary and Alternative Medicine 5
Table 4: Drugs most frequently associated with the identiﬁed adverse drug reactions (ADRs)a.
Drug group (ATC-Code) No (%)
ADRs
Drugs (number of ADRs for each
causative drug)
Adverse drug reactions main
symptoms
CTCAE severity
upgrade (n)
Opioids (N02A) 35
Morphine (23), fentanyl (4),
tramadol (4), oxycodone/naloxone
(1), hydromorphone (1),
oxycodone (1), and piritramide (1)
Constipation (19), nausea (9),
nightmares (3), itching (1),
disorientation (1), seizure (1),
vomiting (1), emesis (1),
hyperacusis (1), sedation (1), and
haemolytic anaemia (1)
Grade II (28)
grade III (7)
Penicillin/beta-lactamase
inhibitors (J01C) 40 Sultamicillin (17), piperacillin (14),
combactam (8), and amoxicillin (1)
Diarrhoea (10), C.
diﬃcile-associated diarrhoea (6),
nausea (3), dyspnoea (2), emesis (2)
allergic reactions (2), drug eruption
(1), renal failure (1), and vaginal
mycosis (1)
Grade II (22)
grade III (17),
and grade IV (1)
Cephalosporin/
Carbapenem (J01D) 36 Cefuroxime (23), ceftriaxone (10),
and imipenem/cilastatin (3)
C. diﬃcile-associated diarrhoea
(12), diarrhoea (6), drug eruption
(6), anaphylactic reaction grade III
(1), seizures (1), tongue swelling
(1), angioedema (1), renal failure
(1), and collapse (1)
Grade II (16),
grade III (16),
grade IV (3),
grade V (1)
Corticosteroids for
Systemic Use (H02AB) 17
Prednisolone (7), dexamethasone
(4), prednisone (5), and
methylprednisolone (1)
Hyperglycaemia (10), psychotic
reaction (2), confusion(1),
hypertension (1), cephalgia (1),
secondary sepsis (1), gastric ulcer
(1), and oesophagitis (1)
Grade II (2),
grade III (11),
grade IV (4),
and grade V (1)
Platelet aggregation
inhibitors excluding
heparin (B01AC)
24 Clopidogrel (6) and ASA (18)
Bleeding (11), anaemia (2),
abdominalpain (1), gastric ulcer
(1), and gastritis (1)
Grade II (14),
grade III (4),
and grade IV (6)
Loop diuretics (C03CA) 16 Furosemide (10) and torasemide(6)
Renal failure acute or chronic (12),
hypotension (2), exsiccosis (2),
itching (1), uraemia (1),
pemphigoid reaction (1), and
electrolyte disorder (1)
Grade II (9),
grade III (4)
grade IV (1),
and grade V (2)
Quinolones (J01M) 15 Levoﬂoxacin (7), ciproﬂoxacin (7),
and moxiﬂoxacin (1)
C. diﬃcile-associated diarrhoea (2),
diarrhoea (2), and increase in GT
(2), alkaline phosphatase(2),
vertigo (1), seizure (1), and
constipation (1)
Grade II (6) and
grade III (9)
Macrolides (J01F) 13 Clarithromycin (9) and
clindamycin (4)
C. diﬃcile-associated diarrhoea (5),
diarrhoea (3), membranous colitis
(1), drug fever, (1) allergic reaction
(1), and drug eruption (1)
Grade II (7) and
grade III (6)
Heparin group (B01AB) 10 Enoxaparin (8) and heparin (2) Bleeding (10)
Grade II (6),
grade III (2),
and grade IV (2)
Oral Antidiabetics (A10B) 11 Metformin (8) and exenatide (3)
Diarrhoea (7), meteorism (4),
abdominalpain (1), nausea (1), and
acute renal failure (1)
Grade II (10)
and grade III (1)
aMultiple drugs may be attributed to one or more symptoms,as well to severity grades (CTCAE).
4.1. ADRs Associated with the Use of AMED. Our main con-
cern was the investigation of the burden of ADRs occurring
in hospitals associated with AMED.
We detectedsix AMED-associated ADRs(2.8%of ADRs)
in approximately 0.27% of AMED-exposed patients, all of
which were of mild severity (CTCAE grade II), and none of
which were serious.
In three cases, the ADR-suspected drugs were mistletoe
extracts associated with three ADRs, all with a probable
causality; arise in temperature>38.5◦C was recorded for two
cases, whereas a local reaction with swelling and reddening
in a diameter of 8 × 8cm was observed in the other. All
these reactions appeared after the ﬁrst administration of the
extracts to the patients. The detection of only three reactions6 Evidence-Based Complementary and Alternative Medicine
Table 5: Adverse drug reactions (ADRs) caused by complementary and alternative medicine (CAM) drugs.
Indication Patients
age, sex
Drug ingredient and
route of application
Concomitantmedication
also possibly related∗ and
route of application
ADR Type of
ADR Causality
Rheumatoid arthritis 62, f Equisetum/Formica s.c. Arnica/levisticum s.c. Local skin reaction
(erythema) B Probable
Rheumatoid arthritis 62, f Mistletoe plant extracta1
s.c. — Local skin reaction
(erythema) (8 × 8cm) A Probable
Mesothelioma cancer 65, m Mistletoe plant extracta2
s.c. —
Temp. >38.6◦C; Local
skin reaction (erythema)
15 × 10cm
A Probable
Breast cancer 41, f Mistletoe plant extracta3
s.c. Pamidronate, i.v Temp. 39.6◦C A Possible
Chronic hepatitis C 35, f Fragaria vesca/Vitis
vinifera p.o.
Maculopapular
exanthema forearms B Possible
Depression 53, f Gentiana, Bryophyllum
p.o. Metamizole p.o. Drug eruption B Possible
∗Drugs for which the causal relationship to the same ADR was also considered to be possible; a1Iscucin salicis A; a2Abnoba viscum fraxini 20mg; a3Helixor
M 1mg. s.c.: subcutaneous,p.o.: per os, i.v. and intravenous.
fulﬁlling these criteria appears to be rather low. This is prob-
ably due to the fact that local reactions of mistletoe are an
indicator of the immunomodulatory action and seen as de-
sired reactions and therefore are not identiﬁed and docu-
mented as exceptional events or even ADRs.
Unfortunately, we cannot perform a precise incidence
calculation from our data since the exact number of patients
exposed is unknown. Even in the case that all 492 patients
in our cohort with a diagnosis of cancer received mistletoe,
0.61% of these patients (3/492) have experienced an ADR.
This calculation probably underestimates the true incidence.
A comparison with the literature shows that the above-
described ADRs are reported in most studies of mistletoe
therapy (mostly concerning tumour patients) and are also
listed in the new summary of product characteristics of the
products (SPC of Helixor, Abnoba, Iscucin and Iscador). In
the case of Abnoba f.ex., ADR rates between 0.9 and 47%
(including local and systemic ADRs) were reported [42].
Accordingto a clinical study of B¨ ussing et al. 21% of patients
treated with mistletoe developed an erythema >3cm[43].
As mistletoe extract is a drug quite frequently adminis-
tered in anthroposophic medicine and the most frequently
prescribed complementary drug in oncology (approx. 12
mio. daily doses in 2007 in Germany) [44], this clinically
important ADR should be a matter of reporting. Indeed
the drug safety database of the Drug Commission of the
German Medical Association (Akd¨ A) includes a list of 113
reports of 349 suspected ADRs in connection with mistletoe
administration up to April 2010 (personal communication).
The sources of these reports include spontaneous reporting
as well as systematic research. Unfortunately, causality is not
uniformlyassessed, and,inmany cases,multiplemedications
were administered, thus hampering a clear correlation of
ADRs and mistletoe.
There is some evidence that the local reactions and prob-
ably also the systemic ADRs (mostly elevated temperature)
are dose dependent and disappear with dose reduction,
whereas the individual dose causing an ADR diﬀers widely
between patients and even the same patient may react in a
diﬀerentway todiﬀerentmistletoepreparations[45].Almost
all reported ADRs had a mild course resulting in complete
recovery [42].
The three other cases of ADRs possibly associated with
AMED occurred in a local reaction (erythema) following the
subcutaneous injection of Equisetum and Formica and of
Arnica and Levisticum. After thereadjustment to oral admin-
istrationofthesedrugs,theerythemadeclined.Hepatodoron
(Fragaria vesca/Vitis vinifera) is one of the most frequently
prescribed AMEDs in our hospital (roughly 1640 daily doses
during the study period, considering theregular prescription
of 4–6 tablets per day) and it is classiﬁed as a possible
causative for the maculopapular exanthema. From 1990 to
April 2010 two suspected ADRs from spontaneous reporting
are listed for hepatodoron in the above-mentioned database
oftheDrugCommissionoftheGermanMedicalAssociation.
AnotherADR-suspected AMEDfromthelist ofmost fre-
quently used AMEDs was bryophyllum together with gen-
tiana. As they were administered concomitantly with meta-
mizole, a drug frequently associated with exanthema, the
causality was classiﬁed as only possible.
In summary, all ADR-suspected AMEDs belong to the
most frequently administered drugs in our hospital. Except
ADRs following mistletoe injections, which are classiﬁed as
probable in all cases, the causality for the other AMEDs was
considered as only possible.
5.Limitations
The exclusion of chemotherapy-induced ADRs could have
led to an underrating of ADRs caused by drugs given con-
comitantly to chemotherapy. This would apply in our study
preferably to ADRs occurring after the frequently coadmin-
istered mistletoe. However, the symptoms caused by mistle-
toe, consisting mainly of local erythema at the injection site,
diﬀer strongly from the symptoms caused by chemotherapy
(e.g., nausea, vertigo) and should not be missed.Evidence-Based Complementary and Alternative Medicine 7
Unfortunately, we were unable to document the medi-
cations of all patients comprehensively, precluding an exact
estimationofincidenceofADRsperprescriptionsorpatients
exposed. Moreover, in the case of AMEDs, neither dose nor
duration of therapy can be standardized, as described (e.g.,
in the case of the pronounced interindividual reactions of
patients to diﬀerent doses and/or preparations of mistletoe).
Therefore, a simpliﬁed calculation using the concept of daily
drug doses (DDD) would give an unreliable and imprecise
estimate of exposure.
As case deﬁnition and causality assessment of ADRs is an
issue in all studies estimating ADRs, we undertook several
measures to provide for a reliable assessment, that is, two
independent physicians used two algorithms in parallel and
in case of disagreements a third assessor and/or medical
specialist was involved.
Finally,thisstudyunlikeotherswasnotdesignedtoassess
eﬀects or eﬃcacy of AMEDs [46].
6.Conclusion
Despite the skepticism towards CAM and AMEDs [47], our
data show that ADR surveillance is possible and a reasonable
safety proﬁle of AMEDS can be assumed. ADRs associated
with allopathic medication detected in our study were com-
parable with regard to incidence and nature to published
data, underlining the comprehensiveness of our prospective
survey.
In summary, our results suggest that ADRs caused by
AMEDsoccuronly with a lowincidenceand produce mainly
mild to moderate symptoms. Since mistletoe extracts were
the predominantly used AMEDs in this cohort of patients,
most ADRs were associated with mistletoe extracts. This
study showed the diﬃculties to comprehensively document
the complete medications of all patients. Thus interpretation
of our results must be done with great caution.
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